The potential of aromatase inhibitors in fish masculinization: a comprehensive review of applications, mechanisms and future perspectives.

Autor: Lal, Jham¹, Vaishnav, Anand¹, Khogen Singh, Soibam¹ gengang@gmail.com, Biswas, Pradyut¹, Kumar Mehta, Naresh¹, Kumar Meena, Dharmendra^1,2 dkmeenacifri@gmail.com, Waikhom, Gusheinzed¹

Publikováno v: International Aquatic Research. Jun2024, Vol. 16 Issue 2, p113-142. 30p.

CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.

Autor: Mulatero P; Division of Internal Medicine and Hypertension, University of Torino, Torino, Italy., Groessl M; Clinic for Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Vogt B; Clinic for Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Schumacher C; DAMIAN Pharma AG, Walchwil, Switzerland., Steele RE; DAMIAN Pharma AG, Walchwil, Switzerland., Brooks A; Covance Clinical Research, Leeds, UK., Hossack S; Covance Clinical Research, Leeds, UK., Brunner HR; Faculty of Biology and Medicine, Lausanne University, Lausanne, Switzerland.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Aug; Vol. 89 (8), pp. 2483-2496. Date of Electronic Publication: 2023 Apr 10.

Letrozole: which dose to be used?

Autor: Buzdar AU, Chaudri HA, Trunet PF

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2000 Apr; Vol. 18 (8), pp. 1802-3.

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

Autor: Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1998 Feb; Vol. 16 (2), pp. 453-61.

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.

Autor: Trunet PF; Department of Research, Pharmaceuticals Division, Ciba-Geigy Limited, Basel, Switzerland., Bhatnagar AS, Chaudri HA, Hornberger U

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 1996; Vol. 35 Suppl 5, pp. 15-8.